Viscosupplementation

Viscosupplementation Market Outlook

The global viscosupplementation market is projected to reach approximately USD 5.75 billion by 2035, growing at a compound annual growth rate (CAGR) of 8.2% during the forecast period. The increasing prevalence of osteoarthritis, especially among the aging population, coupled with the rising demand for non-surgical treatment options, is driving the growth of this market. Additionally, the growing awareness regarding the benefits of viscosupplementation therapies, such as improved joint mobility and pain relief, is further propelling market expansion. Innovations in product formulations, alongside advancements in medical technology, are expected to contribute positively to market dynamics. The trend toward personalized medicine is also anticipated to bolster the adoption of viscosupplementation as tailored therapies address specific patient needs.

Growth Factor of the Market

The viscosupplementation market is primarily driven by the increasing incidence of joint disorders, particularly osteoarthritis, which affects millions of people globally. As the population ages, the demand for effective treatment modalities that can alleviate pain and improve joint function continues to rise. Moreover, the non-invasive nature of viscosupplementation procedures is appealing to patients seeking alternatives to surgery, thus enhancing patient uptake. Advances in product offerings, including innovative formulations and delivery methods, play a crucial role in attracting both healthcare providers and patients. Furthermore, there is a growing emphasis on research and development activities aimed at improving the efficacy and safety of viscosupplementation products, thereby fostering market growth.

Key Highlights of the Market

• The global viscosupplementation market is projected to grow significantly, reaching USD 5.75 billion by 2035.
• North America holds the largest market share, driven by advanced healthcare infrastructure and high prevalence of osteoarthritis.
• Hyaluronic acid-based products dominate the ingredient type segment due to their proven efficacy in joint health.
• There is a noticeable shift towards online pharmacies, providing enhanced accessibility to viscosupplementation products.
• Combination therapy is emerging as a promising product type, combining multiple therapies for improved patient outcomes.

By Product Type

Single Injection:

Single injection viscosupplementation has gained popularity due to its convenience and relatively lower cost compared to multi-injection therapies. This product type involves administering a single dose of hyaluronic acid directly into the affected joint, providing immediate relief from osteoarthritis symptoms. The efficacy of single-injection therapies in reducing pain and improving joint function makes them a preferred choice among patients who seek quick and effective solutions. Additionally, the simplicity of this treatment option aligns with the needs of busy patients who may prioritize less time-consuming procedures. The ease of administration further encourages healthcare practitioners to recommend single injection therapies, contributing to their market growth.

Three Injection:

Three injection viscosupplementation is a common treatment regimen that involves multiple doses administered over a series of weeks. This approach allows for a gradual buildup of hyaluronic acid in the joint, which can lead to prolonged relief from pain and improved mobility. Many patients find this regimen beneficial as it is designed to provide sustained effects rather than immediate but short-term relief. Furthermore, the three-injection protocol is often favored for its balance between patient compliance and efficacy, allowing healthcare providers to monitor patient progress and adjust treatment as necessary. This product type has seen steady growth as clinicians increasingly recognize the advantages of a multi-dose approach for managing osteoarthritis symptoms.

Five Injection:

The five injection treatment regimen represents a more intensive approach to viscosupplementation. Over a period of several weeks, patients receive five separate injections of hyaluronic acid, with the objective of achieving maximum therapeutic benefits. This method is particularly well-suited for patients with more severe osteoarthritis symptoms who require a robust intervention to manage their condition. The extended treatment duration allows for cumulative effects, potentially leading to longer-lasting pain relief and improved joint function. As awareness of the benefits of more intensive therapies grows, the adoption rates of five injection protocols are expected to rise, thereby influencing market dynamics positively.

Combination Therapy:

Combination therapy in viscosupplementation refers to the simultaneous administration of hyaluronic acid with other therapeutic agents, such as platelet-rich plasma (PRP) or corticosteroids. This innovative approach aims to harness the synergistic effects of different treatment modalities, potentially enhancing the overall efficacy of joint injections. Patients undergoing combination therapy may experience reduced pain levels and improved joint mobility more effectively than with single-agent therapies alone. The increasing acceptance of personalized treatment plans in orthopedics has led to a growing interest in combination therapies, which are expected to become a significant segment within the viscosupplementation market.

By Application

Knee Osteoarthritis:

Knee osteoarthritis is the most prevalent application for viscosupplementation, as it affects a significant portion of the population, particularly among older adults. The knee joint is crucial for mobility, and the deterioration of its cartilage can lead to debilitating pain and reduced quality of life. Viscosupplementation provides a much-needed intervention for these patients, offering relief from pain and improved joint function without requiring surgical intervention. The growing recognition of the benefits of viscosupplementation in knee osteoarthritis management is leading to increased adoption among healthcare professionals, which is driving the market forwards significantly.

Hip Osteoarthritis:

Hip osteoarthritis is another critical application area for viscosupplementation therapies. Patients suffering from hip osteoarthritis often experience severe pain that limits their daily activities and overall mobility. Viscosupplementation offers an alternative to invasive surgical procedures, helping to alleviate discomfort and improve joint function. The increasing prevalence of hip osteoarthritis, particularly in aging populations, is anticipated to boost the demand for viscosupplementation, as clinicians seek effective treatments to manage symptoms and enhance patients' quality of life.

Shoulder Osteoarthritis:

Shoulder osteoarthritis is a less common but significant application for viscosupplementation, as it can greatly affect a patient’s ability to perform daily tasks. The shoulder joint is crucial for various movements, and degenerative changes can lead to considerable pain and disability. Viscosupplementation provides a minimally invasive treatment option that can help to reduce inflammation and improve joint function. As awareness regarding the effectiveness of viscosupplementation for shoulder osteoarthritis grows, more healthcare providers are likely to incorporate this treatment into their practice, further expanding the market.

Ankle Osteoarthritis:

Ankle osteoarthritis, while less frequently discussed compared to knee or hip osteoarthritis, can significantly impact patients’ mobility and quality of life. Viscosupplementation can play a crucial role in alleviating pain associated with ankle joint degeneration, providing patients with a more effective alternative to traditional pain management strategies. The growing focus on holistic and comprehensive treatment approaches for joint disorders is leading to an increased interest in using viscosupplementation for ankle osteoarthritis, thereby contributing to market growth.

Others:

In addition to the primary applications of knee, hip, shoulder, and ankle osteoarthritis, viscosupplementation is also being explored for various other joint disorders and conditions. This includes applications for the treatment of osteoarthritis in smaller joints such as the wrist, elbow, and hand. As research into the versatility of viscosupplementation continues to evolve, new indications for its use are likely to emerge. The expansion of the application scope for viscosupplementation therapies will further drive market growth as healthcare providers seek effective solutions for a broader range of joint-related issues.

By Distribution Channel

Hospitals:

Hospitals have traditionally been one of the primary distribution channels for viscosupplementation products. They provide comprehensive orthopedic services, including consultation, diagnosis, and treatment for patients suffering from osteoarthritis. The presence of specialized healthcare professionals, such as orthopedic surgeons, enhances patient trust in receiving viscosupplementation treatments within the hospital setting. Furthermore, hospitals often have the necessary infrastructure and resources to conduct these procedures safely and effectively. As such, this channel's significant contribution to the viscosupplementation market is expected to continue, driven by the increasing demand for orthopedic services.

Orthopedic Clinics:

Orthopedic clinics are emerging as vital distribution channels for viscosupplementation products, as they cater specifically to patients with musculoskeletal disorders. These clinics often provide specialized care and have a strong focus on non-surgical treatment options, making them well-suited for viscosupplementation therapies. Patients prefer orthopedic clinics for their targeted expertise and personalized care, which can lead to improved treatment outcomes. As the trend toward outpatient orthopedic care continues to grow, the role of orthopedic clinics in delivering viscosupplementation is likely to expand, positively influencing market growth.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are increasingly becoming popular venues for viscosupplementation procedures. These facilities allow patients to receive same-day treatment without the need for overnight hospitalization, making the process more convenient and cost-effective. ASCs offer a range of services, including minimally invasive arthroscopic procedures, which can be complemented by viscosupplementation therapies. The growing trend toward outpatient care, along with enhanced patient satisfaction associated with ASCs, is expected to drive the adoption of viscosupplementation within this distribution channel.

Retail Pharmacies:

Retail pharmacies are playing an essential role in the distribution of viscosupplementation products by providing easier access to patients seeking over-the-counter options. Many patients prefer to purchase medications and treatments from their local pharmacies, where they can receive advice from pharmacists about appropriate therapies. The growing acceptance of viscosupplementation for mild to moderate osteoarthritis is leading to an increase in retail pharmacy distribution, making these products more readily available for patients. This convenience is expected to drive market growth, as consumers seek effective treatments that can be easily accessed.

Online Pharmacies:

Online pharmacies are revolutionizing the distribution of viscosupplementation products, providing patients with a modern and convenient option to purchase their treatments. The rise of e-commerce has made it increasingly easy for patients to access a variety of viscosupplementation products from the comfort of their homes. This distribution channel benefits from the increasing trend of telehealth consultations, where patients can discuss their needs with healthcare providers remotely and subsequently order their treatments online. With the convenience and accessibility offered by online pharmacies, this channel is expected to see significant growth, catering to the changing preferences of consumers.

By Ingredient Type

Hyaluronic Acid:

Hyaluronic acid is the most widely used ingredient in viscosupplementation therapies, primarily due to its natural occurrence in the human body and its ability to provide lubrication and hydration to joints. The efficacy of hyaluronic acid in alleviating pain and improving joint function has been well-documented, leading to its widespread acceptance among both patients and healthcare providers. Various formulations and concentrations of hyaluronic acid are available, allowing for tailored treatment options that cater to individual patient needs. As the leading ingredient in viscosupplementation, hyaluronic acid is expected to maintain its dominant position in the market, driven by ongoing research and development activities aimed at enhancing its effectiveness.

Platelet Rich Plasma:

Platelet-rich plasma (PRP) is gaining traction as an innovative ingredient in viscosupplementation due to its regenerative properties and ability to promote healing. PRP therapies involve extracting a sample of the patient's blood, processing it to concentrate the platelets, and injecting it into the affected joint. This method capitalizes on the body’s natural healing mechanisms, making it an attractive alternative to synthetic ingredients. While PRP has been primarily used in sports medicine and injury recovery, its application in osteoarthritis treatment is expanding, leading to increased adoption in the viscosupplementation market. As more research supports its effectiveness, PRP is expected to become a prominent player in this segment.

Corticosteroids:

Corticosteroids are often utilized in conjunction with viscosupplementation therapies to enhance the overall therapeutic effect. These anti-inflammatory agents can help alleviate pain and swelling in the affected joints, making them particularly beneficial for patients with acute symptoms. The combination of corticosteroids with hyaluronic acid or PRP can lead to improved patient outcomes and greater satisfaction. However, the long-term use of corticosteroids is associated with potential side effects, which may limit their application in certain patients. Nevertheless, the demand for combination therapies incorporating corticosteroids is expected to drive their continued presence in the viscosupplementation market.

Others:

In addition to hyaluronic acid, PRP, and corticosteroids, there are several other ingredient types that may be used in viscosupplementation therapies. These may include various biologics, natural extracts, and innovative agents designed to enhance joint health and function. As the market evolves, researchers continue to explore new materials that can improve the effectiveness of viscosupplementation and offer additional treatment options for patients. The exploration of alternative ingredients is anticipated to create new opportunities within the market, appealing to a broader range of patients with diverse needs.

By Region

The regional analysis of the viscosupplementation market reveals significant variations in demand and growth potential across various geographies. North America dominates the market, accounting for approximately 45% of global sales, attributed to the high prevalence of osteoarthritis, advanced healthcare infrastructure, and a growing preference for non-surgical treatment options. The region is also characterized by a robust pipeline of innovative products and a well-established regulatory framework that supports market growth. Europe follows closely, with a market share of around 30%, driven by increasing public awareness of joint health and the availability of diverse viscosupplementation products. The CAGR for Europe is projected to be around 7.5%, highlighting its potential for future growth.

Asia Pacific is expected to exhibit the highest growth rate over the forecast period, with a CAGR of 9.5%, driven by the rising geriatric population and increasing incidences of osteoarthritis. The burgeoning healthcare sector in countries like India and China is facilitating greater access to viscosupplementation therapies, while investments in healthcare infrastructure are improving service delivery. Latin America and the Middle East & Africa are also emerging markets, accounting for smaller market shares but showing promising growth trajectories as awareness of osteoarthritis and its treatment options continues to expand. Overall, the regional dynamics present a diverse landscape for viscosupplementation market players, with opportunities for expansion in both established and emerging markets.

Opportunities

Opportunities in the viscosupplementation market are primarily driven by ongoing research and development initiatives. Continued advancements in product formulations and delivery mechanisms are poised to enhance the efficacy and safety profile of viscosupplementation therapies. For instance, researchers are exploring new combinations of ingredients that could offer even better outcomes for patients suffering from joint disorders. Moreover, the rise of personalized medicine presents a unique opportunity for viscosupplementation providers to develop tailored therapies catered specifically to individual patient profiles. As healthcare providers increasingly seek innovative solutions to improve joint health, these efforts will likely contribute to the market's growth trajectory.

Another significant opportunity lies in the growing acceptance of non-surgical treatment options among patients and healthcare practitioners. As public awareness of the benefits of viscosupplementation increases, more individuals are likely to seek out these therapies as viable alternatives to invasive surgical procedures. Additionally, the expansion of telehealth services and remote patient monitoring is making it easier for patients to access viscosupplementation treatments. This trend is further fueled by the convenience and comfort offered by online pharmacies, allowing patients to obtain their medications without leaving their homes. By capitalizing on these opportunities, industry stakeholders can position themselves favorably in the rapidly evolving viscosupplementation landscape.

Threats

Despite the promising growth prospects for the viscosupplementation market, several threats could impede its progress. One of the primary concerns is the increasing competition from alternative treatment modalities, such as stem cell therapy and other biologic treatments. As new technologies and innovations emerge, patients may opt for these alternatives, drawn by their potential benefits and perceived effectiveness. Healthcare providers may also be hesitant to adopt viscosupplementation therapies if they perceive that these alternatives could offer superior outcomes. This evolving competitive landscape necessitates that viscosupplementation product manufacturers continually innovate and demonstrate the efficacy of their offerings to maintain market share and relevance.

Another significant threat to the viscosupplementation market is regulatory scrutiny and the potential for changing regulations that could impact product approvals and market access. Variations in regulatory requirements across different regions can create challenges for manufacturers seeking to introduce new products or expand their market presence. Additionally, any adverse events or negative publicity associated with viscosupplementation therapies could lead to increased regulation and consumer skepticism. To mitigate these threats, companies should prioritize quality assurance, adhere to stringent regulatory standards, and actively engage in transparent communication with both healthcare professionals and patients.

Competitor Outlook

• Hyaluronic Acid Labs, Inc.
• Sanofi S.A.
• Zimmer Biomet Holdings, Inc.
• Allergan, Inc.
• Regeneron Pharmaceuticals, Inc.
• Amgen, Inc.
• Genzyme Corporation (a Sanofi Company)
• Fidia Farmaceutici S.p.A.
• Teva Pharmaceutical Industries Ltd.
• Medtronic plc
• Orthogen AG
• Merz Pharmaceuticals, LLC
• Innocoll Holdings plc
• Bioventus LLC
• Stryker Corporation

The competitive landscape of the viscosupplementation market is characterized by the presence of both established players and emerging companies vying for market share. Key market participants are continuously investing in research and development to innovate and refine their product offerings, while also focusing on strengthening their distribution networks to reach a broader audience. The competitive environment is further shaped by strategic partnerships, mergers, and acquisitions, enabling companies to expand their capabilities and enhance their market position. As the market evolves, companies must remain agile and responsive to changing consumer preferences and emerging therapeutic trends to maintain their competitive edge.

Major companies such as Sanofi S.A. and Zimmer Biomet Holdings, Inc. have established themselves as leaders in the viscosupplementation market, leveraging their extensive research capabilities and strong brand presence to capture significant market share. Sanofi, for instance, has a diverse portfolio of hyaluronic acid products that cater to various joint disorders, along with a robust global distribution network. Zimmer Biomet also offers a range of viscosupplementation options, with a strong focus on innovation and improving patient outcomes through advanced technology. Their commitment to quality and efficacy has earned them recognition and trust among healthcare professionals and patients alike.

Another notable player, Allergan, Inc., has made significant inroads in the viscosupplementation market through its innovative product offerings and strong marketing strategies. The company’s focus on research and development has led to the introduction of new formulations that provide enhanced benefits for patients with joint disorders. Additionally, Bioventus LLC is gaining traction in the market with its unique approaches to viscosupplementation and its emphasis on biologic therapies. As competition intensifies, these companies and others in the market will need to continually innovate and adapt to meet the evolving needs of patients and healthcare providers.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen, Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Orthogen AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Sanofi S.A.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Bioventus LLC
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Medtronic plc
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Allergan, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Stryker Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Innocoll Holdings plc
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Fidia Farmaceutici S.p.A.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Merz Pharmaceuticals, LLC
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Hyaluronic Acid Labs, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Zimmer Biomet Holdings, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Regeneron Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Teva Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Genzyme Corporation (a Sanofi Company)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Viscosupplementation Market, By Application
    • 6.1.1 Knee Osteoarthritis
    • 6.1.2 Hip Osteoarthritis
    • 6.1.3 Shoulder Osteoarthritis
    • 6.1.4 Ankle Osteoarthritis
    • 6.1.5 Others
  • 6.2 Viscosupplementation Market, By Product Type
    • 6.2.1 Single Injection
    • 6.2.2 Three Injection
    • 6.2.3 Five Injection
    • 6.2.4 Combination Therapy
  • 6.3 Viscosupplementation Market, By Ingredient Type
    • 6.3.1 Hyaluronic Acid
    • 6.3.2 Platelet Rich Plasma
    • 6.3.3 Corticosteroids
    • 6.3.4 Others
  • 6.4 Viscosupplementation Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Orthopedic Clinics
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Retail Pharmacies
    • 6.4.5 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Viscosupplementation Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Viscosupplementation market is categorized based on

By Product Type

• Single Injection
• Three Injection
• Five Injection
• Combination Therapy

By Application

• Knee Osteoarthritis
• Hip Osteoarthritis
• Shoulder Osteoarthritis
• Ankle Osteoarthritis
• Others

By Distribution Channel

• Hospitals
• Orthopedic Clinics
• Ambulatory Surgical Centers
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Hyaluronic Acid
• Platelet Rich Plasma
• Corticosteroids
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Hyaluronic Acid Labs, Inc.
• Sanofi S.A.
• Zimmer Biomet Holdings, Inc.
• Allergan, Inc.
• Regeneron Pharmaceuticals, Inc.
• Amgen, Inc.
• Genzyme Corporation (a Sanofi Company)
• Fidia Farmaceutici S.p.A.
• Teva Pharmaceutical Industries Ltd.
• Medtronic plc
• Orthogen AG
• Merz Pharmaceuticals, LLC
• Innocoll Holdings plc
• Bioventus LLC
• Stryker Corporation